Case study:
Supporting the use of a drug in a new indication: CellCentric

SITUATION

- CCS1477 is a novel small molecule discovered by CellCentric with potential applications in prostate and other cancers
- Having already worked with Physiomics on its Ph1 trial in prostate cancer, CellCentric wanted to choose an appropriate dose/schedule to support dose-escalation in haematological cancer



$$\frac{dR}{dt} = g - d * [Drug]$$

TASK

- Develop pre-clinical model of efficacy in haem cancer
- Swap mouse PK for human PK from Ph1 in prostate cancer
- Assess dosing/ scheduling to determine whether efficacy would be expected

ACTION

- Built preclinical PK-Efficacy models for two relevant cell-lines
- Swapped out preclinical PK for clinical PK and simulated various dosing schedules





RESULT

- Provided client with simulations to support initial dosing/scheduling options for dose-escalation study in a new indication which were used in interactions with local regulatory agency/clinicians
- Clinical protocol approved by regulatory agency

For further information please contact us on:
+44 (0)1865 784980, info@physiomics.co.uk
The Oxford Science Park,
OX4 4GA, Oxford, UK.

Physiomics